Genomic Valley Biotech Ltd

Genomic Valley Biotech Other Announcement

Genomic Valley Biotech Limited received approval from the Registrar of Companies to extend the AGM deadline for FY26 to 31st December 2026. This is a regulatory compliance update.

Genomic Valley Biotech Q1 FY27 Results: Net Profit ₹146,162 Cr, Down 40.7% YoY

Genomic Valley Biotech Ltd reported revenue from operations of ₹380,000 Cr (-57.8% YoY) and net profit of ₹146,162 Cr (-40.7% YoY) for Q1 FY27.

Key figure

Net profit ₹146,162 Cr · -40.7% YoY

Genomic Valley Biotech Board Meeting Date

Genomic Valley Biotech Limited has scheduled a Board Meeting for August 14, 2026. The board will consider and approve unaudited standalone financial results for the June quarter.

Genomic Valley Biotech Q4 FY26 Results: Net Loss of ₹81,745 Cr, Loss Narrows

Genomic Valley Biotech Ltd reported revenue from operations of ₹375,000 Cr (-85.8% YoY) and a net loss of ₹81,745 Cr for Q4 FY26.

Key figure

Net loss ₹81,745 Cr

Genomic Valley Biotech Financial Results

Genomic Valley Biotech approved FY26 audited results, reporting a total revenue of ₹0.27 Crore. The company also appointed Mr. Navjyoti Kumar Jha as Internal Auditor.

Value

₹0.27 Cr

Genomic Valley Biotech Board Meeting Date

Genomic Valley Biotech scheduled a board meeting on May 29, 2026, to approve audited annual financial results. The trading window remains closed until May 31.

Genomic Valley Biotech Other Announcement

Genomic Valley Biotech Ltd's promoter, Yogesh Agrawal, declared that the promoter group made no direct or indirect encumbrances on their shareholding during FY 2025-26. This disclosure complies with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.